NCT06814158View on ClinicalTrials.gov

Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

July 30, 2026

Study Completion Date

December 31, 2026

Conditions
Esophageal Squamour Cell Cancer
Interventions
DRUG

Ivonescimab Combined With Chemotherapy

Ivonescimab 20mg/kg + CT Q3W, 3cycles

Trial Locations (1)

300060

Tianjin Medical University Cancer Hospital, Hexi District

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER